Undisclosed KAT6A degrader / Prelude Therap - LARVOL DELTA

Highly selective KAT6A oral degrader program (GlobeNewswire) - "The Company has selected a development candidate and is on track to file an IND in mid-2026 and initiate a phase 1 dose escalation study in the second half of 2026."

IND • New P1 trial • Estrogen Receptor Positive Breast Cancer

Highly selective KAT6A oral degrader program (GlobeNewswire) - "The Company is now advancing a development candidate and remains on track to file an IND in the first half of 2026."

IND • Estrogen Receptor Positive Breast Cancer • Solid Tumor

Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate anti-cancer activity in pre-clinical models (AACR 2025) - "Lastly, we utilized a predictive assay for neutropenia (CFU-GM), where we found KAT6A-selective degraders were inactive, in contrast to KAT6A/B inhibitors. Our first-in-class KAT6A degraders demonstrated proof-of-concept for a differentiated strategy with potential to improve the depth of response and safety profile for a clinically active anti-cancer target."

Preclinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Oncology • Solid Tumor • ER • HER-2 • KAT6A • KAT6B